By Fineline Cube 
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled Phase II study to evaluate the efficacy and safety of its Brimochol PF in Chinese patients with presbyopia. The study, which has completed its first patient enrollment, is expected to enroll 119 patients across 14 centers, marking a significant step in the development of this novel therapy.
Licensing Agreement with Lunatus
On the same day, Zhaoke entered into a licensing agreement with Dubai-based Lunatus Marketing & Consulting FZCO, granting the firm exclusive rights to import, distribute, promote, market, and sell Brimochol PF in Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Bahrain, and Qatar. Under the terms of the agreement, Lunatus will handle regulatory filings with local authorities, while Zhaoke is entitled to receive milestone payments.
Brimochol PF: Innovation in Presbyopia Treatment
Brimochol PF is a preservative-free fixed-dose combination of carbachol (a choline preparation) and bromonidine tartrate (an α2-receptor agonist). It is designed to correct close-range vision loss due to presbyopia. Zhaoke acquired the rights to the drug through a licensing deal with US-based Visus Therapeutics Inc. in May 2022. Notably, Visus recently merged with UK-headquartered Tenpoint Therapeutics Ltd. and submitted a New Drug Application (NDA) in the US for Brimochol PF last week.-Fineline Info & Tech